Voyageur Pharmaceuticals Ltd. Share Price OTC Markets
Stocks
VYYR.F
CA92918C1014
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1000 USD | -9.09% |
|
0.00% | -23.14% |
| Market Cap | 3.17Cr 2.25Cr 1.98Cr 1.84Cr 1.69Cr 217.76Cr 3.23Cr 22Cr 8.57Cr 106.21Cr 8.44Cr 8.26Cr 368.48Cr | P/E 2024 |
-5.24x | P/E 2025 | -7.5x |
|---|---|---|---|---|---|
| Enterprise Value | 3.15Cr 2.23Cr 1.96Cr 1.82Cr 1.68Cr 216.17Cr 3.2Cr 22Cr 8.51Cr 105.44Cr 8.38Cr 8.2Cr 365.8Cr | EV / Sales 2024 |
-
| EV / Sales 2025 | 2,42,35,81,172x |
| Free-Float |
93.07% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | -9.09% | ||
| Current month | +5.26% | ||
| 1 month | +10.99% | ||
| 3 months | +25.00% | ||
| Current year | -23.14% |
| 1 week | 0.1 | 0.11 | |
| 1 month | 0.09 | 0.11 | |
| Current year | 0.01 | 0.2 | |
| 1 year | 0 | 0.2 | |
| 3 years | 0 | 0.25 | |
| 5 years | 0 | 0.25 | |
| 10 years | 0 | 0.25 |
| Manager | Title | Age | Since |
|---|---|---|---|
Brent Willis
CEO | Chief Executive Officer | - | 01/07/2019 |
| Director of Finance/CFO | - | 17/08/2022 | |
Iryna Saranchova
CTO | Chief Tech/Sci/R&D Officer | - | 17/09/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Brent Willis
BRD | Director/Board Member | - | 06/12/2017 |
Brad Willis
BRD | Director/Board Member | - | 01/07/2019 |
Eric Pommer
CHM | Chairman | - | 30/04/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -9.09% | 0.00% | - | - | 2.33Cr | ||
| +1.97% | +1.43% | +48.44% | +156.66% | 1,03700Cr | ||
| +1.42% | +3.72% | +53.32% | +52.34% | 62TCr | ||
| +1.43% | +0.99% | +34.83% | +78.74% | 45TCr | ||
| +5.14% | +5.84% | +37.54% | +27.28% | 33TCr | ||
| +1.85% | +4.64% | +38.53% | +39.87% | 29TCr | ||
| -0.11% | +0.97% | +22.57% | +17.81% | 26TCr | ||
| +0.25% | -3.10% | -24.44% | -42.25% | 22TCr | ||
| +1.49% | -0.02% | +20.14% | +58.21% | 20TCr | ||
| +0.40% | -3.99% | +15.23% | +62.28% | 16TCr | ||
| Average | +0.48% | +1.12% | +27.35% | +50.10% | 39.53TCr | |
| Weighted average by Cap. | +1.73% | +1.47% | +36.34% | +75.23% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | - | 0.01 0.01 0.01 0.01 0.01 0.8 0.01 0.08 0.03 0.39 0.03 0.03 1.36 |
| Net income | -17.07L -12.11L -10.65L -10L -9L -12Cr -17.38L -1.18Cr -46.17L -5.72Cr -45.48L -44.5L -20Cr | -35.33L -25.07L -22.05L -20.48L -18.84L -24Cr -35.96L -2.45Cr -95.53L -12Cr -94.11L -92.07L -41Cr |
| Net Debt | -1L -79.92T -70.29T -65.3T -60.06T -77.4L -1L -8L -3L -37.75L -3L -3L -1.31Cr | -2L -2L -1L -1L -1L -1.58Cr -2L -15.98L -6L -77.28L -6L -6L -2.68Cr |
Employees
-
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/26/22 | $0.1000 | -9.09% | 47,000 |
| 21/26/21 | $0.1100 | +10.00% | 39,000 |
| 20/26/20 | $0.1000 | 0.00% | 14,000 |
| 17/26/17 | $0.1000 | 0.00% | 6,000 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- VM Stock
- VYYR.F Stock
Select your edition
All financial news and data tailored to specific country editions
















